Low serum Irisin levels were found to be a predictor of poor early functional outcome in ischemic stroke patients [112] adding value to the potential of its development as a prognostic biomarker, as was Chemokine (C-C motif) ligand 2 (CCL2) levels in blood or cerebrospinal fluid, which were found to correlate with the clinical symptoms of stroke patients [113]. This evidence concerns the gene CCL2 and ischemic stroke.